vs
Side-by-side financial comparison of Public Service Enterprise Group (PEG) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.3B vs $1.5B, roughly 1.5× Public Service Enterprise Group). Public Service Enterprise Group runs the higher net margin — 50.6% vs 26.6%, a 24.0% gap on every dollar of revenue. On growth, Public Service Enterprise Group posted the faster year-over-year revenue change (7.0% vs 2.9%). Over the past eight quarters, Zoetis's revenue compounded faster (-2.1% CAGR vs -22.3%).
The Public Service Enterprise Group, Inc. (PSEG) is a publicly traded energy company based in Newark, New Jersey, where it has been based since its founding. It was founded in 1985, with its roots tracing back to 1903.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
PEG vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $2.3B |
| Net Profit | $741.0M | $601.0M |
| Gross Margin | — | 71.7% |
| Operating Margin | 73.4% | — |
| Net Margin | 50.6% | 26.6% |
| Revenue YoY | 7.0% | 2.9% |
| Net Profit YoY | 25.8% | -0.2% |
| EPS (diluted) | — | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.5B | $2.3B | ||
| Q4 25 | $2.9B | $2.4B | ||
| Q3 25 | $3.2B | $2.4B | ||
| Q2 25 | $2.8B | $2.5B | ||
| Q1 25 | $3.2B | $2.2B | ||
| Q4 24 | $2.5B | $2.3B | ||
| Q3 24 | $2.6B | $2.4B | ||
| Q2 24 | $2.4B | $2.4B |
| Q1 26 | $741.0M | $601.0M | ||
| Q4 25 | $315.0M | $603.0M | ||
| Q3 25 | $622.0M | $721.0M | ||
| Q2 25 | $585.0M | $718.0M | ||
| Q1 25 | $589.0M | $631.0M | ||
| Q4 24 | $286.0M | $581.0M | ||
| Q3 24 | $520.0M | $682.0M | ||
| Q2 24 | $434.0M | $624.0M |
| Q1 26 | — | 71.7% | ||
| Q4 25 | — | 70.2% | ||
| Q3 25 | — | 71.5% | ||
| Q2 25 | — | 73.6% | ||
| Q1 25 | — | 72.0% | ||
| Q4 24 | — | 69.5% | ||
| Q3 24 | — | 70.6% | ||
| Q2 24 | — | 71.7% |
| Q1 26 | 73.4% | — | ||
| Q4 25 | 17.5% | 31.9% | ||
| Q3 25 | 26.5% | 37.0% | ||
| Q2 25 | 29.1% | 36.7% | ||
| Q1 25 | 24.7% | 36.5% | ||
| Q4 24 | 18.1% | 31.6% | ||
| Q3 24 | 24.3% | 36.6% | ||
| Q2 24 | 24.0% | 33.0% |
| Q1 26 | 50.6% | 26.6% | ||
| Q4 25 | 10.8% | 25.3% | ||
| Q3 25 | 19.3% | 30.0% | ||
| Q2 25 | 20.9% | 29.2% | ||
| Q1 25 | 18.3% | 28.4% | ||
| Q4 24 | 11.6% | 25.1% | ||
| Q3 24 | 19.7% | 28.6% | ||
| Q2 24 | 17.9% | 26.4% |
| Q1 26 | — | $1.42 | ||
| Q4 25 | $0.63 | $1.37 | ||
| Q3 25 | $1.24 | $1.63 | ||
| Q2 25 | $1.17 | $1.61 | ||
| Q1 25 | $1.18 | $1.41 | ||
| Q4 24 | $0.57 | $1.29 | ||
| Q3 24 | $1.04 | $1.50 | ||
| Q2 24 | $0.87 | $1.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $17.3M | — |
| Total Assets | — | — |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $132.0M | — | ||
| Q3 25 | $334.0M | $2.1B | ||
| Q2 25 | $186.0M | $1.4B | ||
| Q1 25 | $894.0M | $1.7B | ||
| Q4 24 | $125.0M | $2.0B | ||
| Q3 24 | $203.0M | $1.7B | ||
| Q2 24 | $113.0M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | $22.5B | — | ||
| Q3 25 | $22.5B | — | ||
| Q2 25 | $22.6B | — | ||
| Q1 25 | $23.0B | — | ||
| Q4 24 | $21.1B | — | ||
| Q3 24 | $21.4B | — | ||
| Q2 24 | $20.5B | — |
| Q1 26 | $17.3M | — | ||
| Q4 25 | $17.0B | $3.3B | ||
| Q3 25 | $17.0B | $5.4B | ||
| Q2 25 | $16.7B | $5.0B | ||
| Q1 25 | $16.4B | $4.7B | ||
| Q4 24 | $16.1B | $4.8B | ||
| Q3 24 | $16.1B | $5.2B | ||
| Q2 24 | $15.8B | $5.0B |
| Q1 26 | — | — | ||
| Q4 25 | $57.6B | $15.5B | ||
| Q3 25 | $56.9B | $15.2B | ||
| Q2 25 | $56.0B | $14.5B | ||
| Q1 25 | $55.6B | $14.1B | ||
| Q4 24 | $54.6B | $14.2B | ||
| Q3 24 | $54.1B | $14.4B | ||
| Q2 24 | $52.4B | $14.2B |
| Q1 26 | — | — | ||
| Q4 25 | 1.33× | — | ||
| Q3 25 | 1.33× | — | ||
| Q2 25 | 1.36× | — | ||
| Q1 25 | 1.40× | — | ||
| Q4 24 | 1.31× | — | ||
| Q3 24 | 1.33× | — | ||
| Q2 24 | 1.30× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PEG
| Residential Sales | $792.0M | 54% |
| Commercial & Industrial | $511.0M | 35% |
| Other | $161.0M | 11% |
ZTS
| Companion Animal | $1.5B | 67% |
| Livestock | $720.0M | 32% |
| Contract Manufacturing & Human Health | $23.0M | 1% |
